In this article, the possible mechanisms involved in the efficacy of treatment using TNF-blocking agents are discussed. Cite this: Anti-TNF-α Agents in the Treatment of Immune-mediated ...

Suggestions that rheumatoid arthritis (RA) patients suffer more cardiovascular events when treated with Janus kinase (JAK) inhibitors compared with tumor necrosis factor (TNF) blockers or other ...

Do Anti-TNF Drugs Increase the Risk of Malignancies? TNF-α plays an important role in surveillance of malignancy [88] and hence there is a theoretical risk of increased tumor formation with anti ...

Discover the signs of psoriatic arthritis, from joint pain and skin changes to nail damage and fatigue, plus the latest ...

Neuroimmune modulation represents a promising treatment strategy that uses vagus nerve stimulation to reduce inflammation in RA.

Background Muscle wasting and weakness (sarcopenia) are commonly associated with COPD causing frailty and reduced quality of ...

SUNRISE-PD evaluating the Company’s anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson’s disease who have not ...

That only came more recently, as patent expiries for the blockbuster anti-TNF class of arthritis drugs approached. Now that the likes of Remicade (infliximab), Enbrel (etanercept) and, most ...

Having psoriasis raises your risk of psoriatic arthritis — and rheumatoid arthritis, too. Make sure you can tell these two forms of arthritis apart.

anti-CD40L antibody frexalimab which is in mid-stage testing for multiple sclerosis, and SAR441566, an orally-active TNF blocker that Sanofi thinks could be the biggest drug it has ever developed.